RallybioRLYB
About: Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Employees: 25
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
2.93% more ownership
Funds ownership: 75.23% [Q3] → 78.16% (+2.93%) [Q4]
0% more funds holding
Funds holding: 49 [Q3] → 49 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
15% less capital invested
Capital invested by funds: $36.5M [Q3] → $31.1M (-$5.39M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for RLYB.
Financial journalist opinion
Based on 4 articles about RLYB published over the past 30 days









